Skip to Main Content
Contribute Try STAT+ Today

As the White House struggles to address the pandemic and other pressing health matters, a public tug-of-war has emerged over who should be tapped to run the Food and Drug Administration.

In recent weeks, competing missives have been issued urging the Biden administration to choose either Janet Woodcock, a long-standing FDA official who some perceive to be unnecessarily sympathetic to industry, or Joshua Sharfstein, who has also served at the agency and has a public health background, but is seen as less supportive of industry concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is really a tough choice. I’ve admired Janet Woodcock’s long drive to get drug companies to use regulatory science in drug development and she’s been instrumental in developing the principles of that regulatory science. But I don’t have any details on what she was doing during Trump’s reign, and that’s important to know. FDA has really lost a great deal of credibility. The numbers of people who are resisting COVID-19 vaccination proof of that. I’m also concerned about all the great people at FDA who have had to endure the Trump years. Who is best able to restore their morale? Whoever leads it must be able to show that a new broom sweeps clean, so I lean toward Dr. Sharfstein. FDA is above all the the agency that safeguards public health. I wonder if the agency doesn’t need an Inspector General role to help assess the health of FDA itself.

Comments are closed.